Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
PR Newswire•11/08/2026•08:00 ET
0
Whiz Insights
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
SOLANA BEACH, Calif. and AHMEDABAD, India and LONDON, Aug. 11, 2026
Get started
Create a free account to read the full story.